Adaptive Biotechnologies Corporation (ADPT) |
|
48.63 0.59 (1.23%)
|
09-30 18:12 |
|
Open: |
47.51 |
Pre. Close: |
48.04 |
|
High:
|
48.76 |
Low:
|
47.2 |
|
Volume:
|
685,886 |
Market Cap:
|
6,604M |
|
|
|
|
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 346 full-time employees. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. The company offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. The company also focuses on developing immune-mediated therapies in oncology and other disease areas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
48.796 - 49.027 |
49.027 - 49.244 |
|
Low:
|
46.61 - 46.875 |
46.875 - 47.124 |
|
Close:
|
48.191 - 48.611 |
48.611 - 49.006 |
|
Technical analysis |
as of: 2020-09-30 4:38:18 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 59.21 One year: 69.16 |
| Support: |
Support1: 40.84 Support2: 34.75 |
| Resistance: |
Resistance1: 50.70 Resistance2: 59.21 |
| Pivot: |
45.83 |
| Moving Average: |
MA(5): 47.83 MA(20): 43.81
MA(100): 41.84 MA(250): 33.85 |
| MACD: |
MACD(12,26): 2.11 Signal(9): 1.70 |
| Stochastic oscillator: |
%K(14,3): 86.93  %D(3): 89.45 |
| RSI: |
RSI(14): 65.08 |
| 52-week: |
High: 50.70 Low: 15.19 Change(%): 57.3 |
| Average Vol(K): |
3-Month: 107469 10-Days: 126543 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.ADPT has closed below upper band by 25.8%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 30 Sep 2020
Adaptive Biotechnologies Corporation (ADPT) market price of $48.04 offers the impression of an exciting value play - The InvestChronicle
Wed, 30 Sep 2020
Adaptive Biotechnologies Corporation (ADPT): What is good about stock? - Marketing Sentinel
Wed, 30 Sep 2020
Is a Correction Looming Ahead for Adaptive Biotechnologies Corporation (ADPT) - The News Heater
Tue, 29 Sep 2020
Strong Buy Adaptive Biotechnologies Corporation [ADPT] Stock Before Shares Hit Major Turbulence - MZP News
Tue, 29 Sep 2020
Adaptive Biotechnologies Corp (ADPT) Stock: Buy, Hold, or Sell? - InvestorsObserver
Mon, 28 Sep 2020
Do Hedge Funds Love Adaptive Biotechnologies Corporation (ADPT)? - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
136 |
| Shares Float (M) |
82 |
|
% Held by Insiders
|
5.47 |
|
% Held by Institutions
|
73.44 |
|
Shares Short (K)
|
3,040 |
|
Shares Short P. Month (K)
|
2,210 |
Stock Financials |
|
EPS
|
-0.790 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
4.130 |
|
Profit Margin
|
-107.96 |
|
Operating Margin
|
-123.44 |
|
Return on Assets (ttm)
|
-9.8 |
|
Return on Equity (ttm)
|
-24.6 |
|
Qtrly Rev. Growth
|
-5.2 |
|
Gross Profit (p.s.)
|
-0.058 |
|
Sales Per Share
|
0.679 |
|
EBITDA (p.s.)
|
-0.778 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-120 |
|
Levered Free Cash Flow (M)
|
-51 |
Stock Valuations |
|
PE Ratio
|
-61.56 |
|
PEG Ratio
|
|
|
Price to Book value
|
11.77 |
|
Price to Sales
|
71.64 |
|
Price to Cash Flow
|
-55.21 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
